CN106619972B - Capsule for reducing blood sugar containing hirsutella hepiali Chen et Shen mycelium powder, and its preparation method and application - Google Patents
Capsule for reducing blood sugar containing hirsutella hepiali Chen et Shen mycelium powder, and its preparation method and application Download PDFInfo
- Publication number
- CN106619972B CN106619972B CN201710014390.1A CN201710014390A CN106619972B CN 106619972 B CN106619972 B CN 106619972B CN 201710014390 A CN201710014390 A CN 201710014390A CN 106619972 B CN106619972 B CN 106619972B
- Authority
- CN
- China
- Prior art keywords
- capsule
- powder
- hirsutella
- blood sugar
- hirsutella hepiali
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/066—Clavicipitaceae
- A61K36/068—Cordyceps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Abstract
The invention discloses a capsule for reducing blood sugar by using hirsutella hepiali Chen et Shen mycelium powder, which comprises the following raw materials: 200-300 g of hirsutella hepiali Chen et Shen mycelium powder, 270-410 g of fructus Schisandrae chinensis and 240-360 g of ginseng. The invention also provides a preparation method and application thereof. The capsule for reducing blood sugar of hirsutella hepiali mycelia powder has excellent effect of reducing blood sugar, and is safe, effective and free of side effect.
Description
Technical Field
The invention relates to a capsule for reducing blood sugar, in particular to a capsule for reducing blood sugar from hirsutella hepiali mycelia powder, a preparation method and application thereof.
Background
Diabetes mellitus is a metabolic disorder characterized primarily by impaired glucose metabolism induced by defective insulin secretion and action, resulting in an imbalance in glucose homeostasis. Type I diabetes and type II diabetes are classified according to whether insulin is dependent. The main characteristic of diabetes mellitus II is the diminished biological effect of insulin-dependent tissues on insulin, also known as "insulin resistance" and defects in the beta cells of the islets of langerhans, which cause fasting and postprandial hyperglycemia in patients. According to statistics, the number of diabetics in the world is nearly 1.5 hundred million (about 20 percent in China) in 2000. With the continuous improvement of living standard of people, the incidence of obesity and diabetes is increasing year by year. Recent epidemiological investigations have shown that the incidence of diabetes in the 2010 middle-aged adults is as high as 11.6%, of which more than 90% are non-insulin-dependent type II diabetes.
at present, the method of chemically synthesizing medicaments such as insulin and analogues thereof is generally adopted in the market and clinically for long-term injection to maintain the blood sugar level of a patient, so that sequelae such as permanent nerve injury, hypoglycemia, lactic acidosis and special hepatocyte injury are easily caused, and the economic burden of the patient is greatly increased. The traditional Chinese medicine preparation and the natural water extract have proven exact curative effects in hundreds of years of diabetes treatment history, which not only can improve the life quality of patients, but also can delay the development of complications. In recent years, more and more research has been focused on the development of natural hypoglycemic agents for preventing and reducing complications and the like induced by abnormal blood glucose.
paecilomyces hepiali (Paccilomyces hepiali) is a hirsutella hepiali mycelium powder which is separated from wild cordyceps sinensis stroma and has a fingerprint spectrum highly similar to that of cordyceps sinensis. The paecilomyces hepiali contains various sterols and a large amount of fatty acids, and has biological activities of resisting tumor, regulating immunity, resisting fatigue, resisting anoxia, etc. However, no relevant research is available on the hypoglycemic activity.
disclosure of Invention
Aiming at the defects in the prior art, the invention aims to provide a safe and effective blood sugar reducing capsule.
The purpose of the invention is realized by the following technical scheme:
a capsule for reducing blood sugar is prepared from hirsutella hepiali Chen et Shen mycelium powder: 200-300 g of hirsutella hepiali Chen et Shen mycelium powder, 270-410 g of fructus Schisandrae chinensis and 240-360 g of ginseng.
preferably, the hepialus hirsutella mycelium powder blood sugar reducing capsule comprises the following raw materials: 250g of hirsutella hepiali Chen et Shen mycelium powder, 340g of Chinese magnoliavine fruit and 300g of ginseng.
The invention also provides a preparation method of the capsule for reducing blood sugar by using the hirsutella hepiali mycelia powder, which comprises the following steps:
(1) weighing ginseng and schisandra chinensis according to a ratio, cleaning, adding 5-6L of 75 mass percent ethanol, extracting under reflux for 2 times, 1-2 hours each time, filtering the extracting solution, removing the residues, combining the filtrates, performing reduced pressure evaporation, recovering the ethanol, concentrating the filtrate to an extract with a relative density of 1.30-1.35 g/cm 3 (60 ℃), drying under reduced pressure to obtain a dry paste, crushing, and sieving with a 80-mesh sieve to obtain a dry paste powder;
(2) Weighing hirsutella hepiali mycelia powder according to a ratio, cleaning, mixing with the dry extract powder obtained in the step (1), wetting with 85% ethanol by mass fraction to prepare soft materials, granulating, drying at 55-60 ℃, grading to obtain 0.3 g/granule of hirsutella hepiali mycelia powder, and encapsulating into capsule shells.
Preferably, the first and second liquid crystal materials are,
The reduced pressure evaporation condition of the step (1) is-0.065 to-0.075 MPa, 65 ℃;
The reduced pressure drying condition of the step (1) is-0.085 Mpa, 65 ℃;
The granulation in the step (2) is 16-mesh granulation, and the whole granules are 14-mesh granules;
and (3) the capsule shell in the step (2) is a 0# capsule shell.
the invention also provides application of the hirsutella hepiali mycelia powder hypoglycemic capsules in preparation of hypoglycemic drugs or health care products.
The capsule for reducing blood sugar of hirsutella hepiali mycelia powder has excellent effect of reducing blood sugar, and is safe, effective and free of side effect.
Detailed Description
The present invention will be further described with reference to the following examples, which are intended to be illustrative only and not to be limiting of the invention in any way, and any person skilled in the art can modify the present invention by applying the teachings disclosed above and applying them to equivalent embodiments with equivalent modifications. Any simple modification or equivalent changes made to the following embodiments according to the technical essence of the present invention, without departing from the technical spirit of the present invention, fall within the scope of the present invention.
The drugs and instruments used in the examples were as follows:
Hirsutella hepiali mycelia powder purchased from Qinghai Zhufeng Cordyceps sinensis raw materials Co., Ltd, lot number: ZF0116F 002.
Streptozotocin (STZ) was purchased from Sigma-Aldrich, glibenclamide from Henan Ling Rui pharmaceutical Co., Ltd, DMEM high sugar medium from Gibco, fetal bovine serum from Sijiqing, trypsin and diabase (penicillin, streptomycin) were both purchased from Solarbio, DCFH-DA from Sigma, and biochemical reagents were all home analytical reagents purchased from the national pharmaceutical group.
An experimental detection kit: mouse triglyceride, cholesterol kits were purchased from Shanghai-derived leaf Bioagent, Inc.
The test mice are 4-week-old C57BL/6j mice, and are male, and the weight of the test mice is 18-22 g. The certification number is SCXK- (Ji) 2015-0001, provided by the institute of biological products of Changchun.
The instrument comprises the following steps: GSY-II constant temperature water bath (Beijing medical equipment factory); GENESIS SQ 25ES model lyophilizer (USA); SMF-320A multistage flash evaporator (Henan gold tripod science) SYNERGY4 microplate reader (Biotek U.S. Berton).
Example 1
The capsule for reducing blood sugar containing hirsutella hepiali mycelia powder of example 1 is prepared by the following method:
(1) Weighing 300g of ginseng and 340g of schisandra chinensis, cleaning, adding 5L of 75 mass percent ethanol, performing reflux extraction for 2 times, each time for 2 hours, filtering the extracting solution, removing medicine residues, combining the filtrates, performing reduced pressure evaporation at-0.065 MPa and 65 ℃, recovering ethanol, concentrating the filtrate to obtain an extract with the relative density of 1.30-1.35 g/cm 3 (60 ℃), performing reduced pressure drying at-0.085 MPa and 65 ℃ to obtain a dry paste, crushing, and sieving with a 80-mesh sieve to obtain dry paste powder;
(2) weighing 250g of hirsutella hepiali Chen et Shen mycelium powder, cleaning, mixing with the dry extract powder obtained in the step (1), wetting with 85% ethanol by mass fraction to prepare soft material, granulating with 16 mesh sieve, drying at 55 ℃, grading with 14 mesh sieve to obtain 0.3 g/granule of hirsutella hepiali Chen et Shen mycelium powder for lowering blood sugar, and encapsulating into 0# capsule shell.
Example 2
The hypoglycemic capsule of example 2 is prepared by the following method:
(1) Preparing a ginseng aqueous extract: pulverizing 300g Ginseng radix into fine powder, adding deionized water at a ratio of 1:60g/ml, heating and extracting at 85 deg.C for 3 times (each time for 3 hr) at 1500rpm for 10min, filtering, concentrating the filtrate with multi-stage flash evaporator, and lyophilizing to obtain Ginseng radix water extract;
(2) preparing a schisandra chinensis aqueous extract: pulverizing 340g fructus Schisandrae into fine powder, adding deionized water at a ratio of 1:60g/ml, heating and extracting at 85 deg.C for 3 times (each time for 3 hr) at 1500rpm for 10min, filtering, concentrating the filtrate with multi-stage flash evaporator, and lyophilizing to obtain fructus Schisandrae water extract;
(3) Preparing a hirsutella hepiali mycelium powder aqueous extract: soaking 250g hirsutella hepiali Chen et Shen mycelium powder in deionized water at a ratio of 1:60g/ml, heating and extracting at 85 deg.C for 3 times (each time for 3 hr), centrifuging at 1500rpm for 10min, filtering, concentrating the filtrate with multi-stage flash evaporator, and lyophilizing to obtain hirsutella hepiali Chen et Shen mycelium powder water extract;
(4) Uniformly mixing the obtained ginseng water extract, the schisandra water extract and the hirsutella hepiali mycelia powder water extract, wetting the mixture by using 85% of ethanol in mass fraction to prepare a soft material, granulating the soft material by using a 16-mesh sieve, drying the soft material at 55-60 ℃, and finishing the granules by using a 14-mesh sieve to obtain 0.3 g/granule of the hypoglycemic capsule, and filling the capsule into a 0# capsule shell.
Example 3
The hypoglycemic capsule of example 3 is prepared by the following method:
(1) preparing a ginseng aqueous extract: pulverizing 300g Ginseng radix into fine powder, adding deionized water at a ratio of 1:60g/ml, heating and extracting at 85 deg.C for 3 times (each time for 3 hr) at 1500rpm for 10min, filtering, concentrating the filtrate with multi-stage flash evaporator, and lyophilizing to obtain Ginseng radix water extract;
(2) preparing a schisandra chinensis aqueous extract: pulverizing 340g fructus Schisandrae into fine powder, adding deionized water at a ratio of 1:60g/ml, heating and extracting at 85 deg.C for 3 times (each time for 3 hr) at 1500rpm for 10min, filtering, concentrating the filtrate with multi-stage flash evaporator, and lyophilizing to obtain fructus Schisandrae water extract;
(3) Weighing 250g of hirsutella hepiali Chen et Shen mycelium powder, cleaning, mixing with Ginseng radix water extract, fructus Schisandrae water extract, and hirsutella hepiali Chen et Shen mycelium powder water extract, wetting with 85% ethanol by mass fraction to obtain soft material, granulating with 16 mesh sieve, drying at 55-60 deg.C, grading with 14 mesh sieve to obtain 0.3 g/granule of hirsutella hepiali Chen et Shen mycelia powder, and encapsulating into 0# capsule shell.
Example 4
The hypoglycemic capsule of example 4 is prepared by the following method:
(1) Preparing ginseng alcohol extract, namely crushing 300g of ginseng into fine powder, adding 2.5L of ethanol with the mass fraction of 75% for reflux extraction for 2 times, each time lasting 2 hours, filtering the extracting solution, removing medicine residues, combining the filtrates, performing reduced pressure evaporation at the temperature of 65 ℃ under the pressure of-0.065 to-0.075 MPa, recovering the ethanol, concentrating the filtrate to an extract with the relative density of 1.30 to 1.35g/cm 3 (60 ℃), drying under the pressure of-0.085 MPa at the temperature of 65 ℃ to obtain dry extract, crushing, and sieving by a sieve of 80 meshes to obtain the ginseng alcohol extract;
(2) preparing an ethanol extract of schisandra chinensis, namely crushing 340g of schisandra chinensis into fine powder, adding 2.5L of ethanol with the mass fraction of 75% for reflux extraction for 2 times, each time for 2 hours, filtering the extract, removing medicine residues, combining the filtrates, performing reduced pressure evaporation at 65 ℃ under the pressure of-0.065 to-0.075 MPa, recovering ethanol, concentrating the filtrate to an extract with the relative density of 1.30 to 1.35g/cm 3 (60 ℃), drying under the reduced pressure of-0.085 MPa at 65 ℃ to obtain a dry extract, crushing, and sieving by a 80-mesh sieve to obtain the ethanol extract of schisandra chinensis;
(3) Preparing hirsutella hepiali mycelia powder ethanol extract, namely crushing 250g of ginseng into fine powder, adding 2.5L of 75 mass percent ethanol for reflux extraction for 2 times, each time for 2 hours, filtering the extract, removing dregs of decoction, merging the filtrate, performing reduced pressure evaporation at 65 ℃ under the pressure of-0.065 to-0.075 MPa, recovering the ethanol, concentrating the filtrate to obtain an extract with the relative density of 1.30 to 1.35g/cm 3 (60 ℃), drying under the reduced pressure at 65 ℃ under the pressure of-0.085 MPa to obtain dry paste, crushing, and sieving by a 80-mesh sieve to obtain hirsutella hepiali mycelia powder ethanol extract;
(4) Uniformly mixing the obtained ginseng alcohol extract, schisandra alcohol extract and hirsutella hepiali mycelia powder alcohol extract, wetting the mixture by using 85% of ethanol by mass fraction to prepare a soft material, granulating the soft material by using a 16-mesh sieve, drying the soft material at 55-60 ℃, and finishing the granules by using a 14-mesh sieve to obtain 0.3 g/granule of the blood sugar reducing capsule, and filling the capsule into a 0# capsule shell.
Comparative example 1
The hypoglycemic capsule of comparative example 1 was prepared by the following method:
(1) weighing 640g of ginseng, cleaning, adding 5-6L of 75 mass percent ethanol, performing reflux extraction for 2 times, each time for 1-2 hours, filtering the extracting solution, removing medicine residues, combining the filtrates, performing reduced pressure evaporation at-0.065 to-0.075 MPa and 65 ℃, recovering ethanol, concentrating the filtrate to obtain an extract with the relative density of 1.30-1.35 g/cm 3 (60 ℃), drying under reduced pressure at-0.085 MPa and 65 ℃ to obtain a dry extract, crushing, and sieving with a 80-mesh sieve to obtain dry extract powder;
(2) weighing 250g of hirsutella hepiali Chen et Shen mycelium powder, cleaning, mixing with the dry extract powder obtained in step (1), wetting with 85% ethanol by mass fraction to obtain soft material, granulating with 16 mesh sieve, drying at 55-60 deg.C, grading with 14 mesh sieve to obtain 0.3 g/granule of blood sugar lowering capsule, and encapsulating into 0# capsule shell.
Comparative example 2
The hypoglycemic capsule of comparative example 2 was prepared by the following method:
(1) Weighing 640g of schisandra chinensis, cleaning, adding 5-6L of 75 mass percent ethanol, performing reflux extraction for 2 times, each time lasting 1-2 hours, filtering the extracting solution, removing medicine residues, combining the filtrates, performing reduced pressure evaporation at-0.065-0.075 MPa and 65 ℃, recovering ethanol, concentrating the filtrate to obtain an extract with the relative density of 1.30-1.35 g/cm 3 (60 ℃), performing reduced pressure drying at-0.085 MPa and 65 ℃ to obtain a dry paste, crushing, and sieving with a 80-mesh sieve to obtain a dry paste powder;
(2) weighing 250g of hirsutella hepiali Chen et Shen mycelium powder, cleaning, mixing with the dry extract powder obtained in step (1), wetting with 85% ethanol by mass fraction to obtain soft material, granulating with 16 mesh sieve, drying at 55-60 deg.C, grading with 14 mesh sieve to obtain 0.3 g/granule of blood sugar lowering capsule, and encapsulating into 0# capsule shell.
Comparative example 3
The hypoglycemic capsule of comparative example 3 was prepared by the following method:
(1) weighing 300g of ginseng and 340g of schisandra chinensis, cleaning, adding 5-6L of 75 mass percent ethanol, carrying out reflux extraction for 2 times, each time lasting 1-2 hours, filtering the extracting solution, removing medicine residues, combining the filtrates, carrying out reduced pressure evaporation at 65 ℃ under-0.065-0.075 MPa, recovering ethanol, concentrating the filtrate to obtain an extract with a relative density of 1.30-1.35 g/cm 3 (60 ℃), drying at 65 ℃ under-0.085 MPa to obtain a dry paste, crushing, and sieving with a 80-mesh sieve to obtain a dry paste powder;
(2) wetting the dry paste powder obtained in the step (1) with 85% ethanol by mass fraction to prepare a soft material, granulating with a 16-mesh sieve, drying at 55-60 ℃, grading with a 14-mesh sieve to obtain 0.3 g/granule of the hypoglycemic capsule, and filling into a 0# capsule shell.
Comparative example 4
the hypoglycemic capsule of comparative example 4 was prepared by the following method:
Weighing 250g of hirsutella hepiali Chen et Shen mycelium powder, wetting with 85% ethanol by mass to prepare soft material, granulating with 16 mesh sieve, drying at 55-60 deg.C, grading with 14 mesh sieve to obtain 0.3 g/granule of blood sugar lowering capsule, and encapsulating into 0# capsule shell.
test example 1 hypoglycemic test for STZ-induced type II diabetic mice
The hypoglycemic effects of the hypoglycemic capsules prepared in examples 1 to 4 and comparative examples 1 to 4 were tested.
C57BL/6j mice are subjected to intraperitoneal injection of 120mg/kg STZ on day 0 to establish a diabetes model (the STZ is dissolved in 0.11mol/L, pH 4.2.2 citric acid/sodium citrate buffer solution, the buffer solution is prepared immediately and stored in ice bath), fasting blood glucose is tested, the successfully modeled diabetes mice are divided into 10 groups according to modeling results, 10 mice in each group are used, and the average blood glucose value in each group is 18.00-19.00 mmol/L. The 10 groups were 4 example groups, 4 comparative example groups, 1 positive control group, and 1 negative control group, respectively. A group of healthy controls, i.e. healthy mice not modeled by STZ, was also set, 10. Thereafter, mice were treated by gavage once a day for 20 days, and positive control group was given Glibenclamide (Glibenclamide, GLI) at 0.2mg/kg a day; the groups of examples 1-2 and comparative examples 1-4 were each administered 4g/kg of a hypoglycemic capsule (the dosages were calculated by weight after removing the capsule shell). The negative control group and the healthy control group were not administered. The general condition of the mice was observed daily and fasting blood glucose was recorded on days 0, 10 and 20 and measured on day 20. Before blood collection, mice are fasted and freely collected with water for 24h, anticoagulated blood is taken from the intraocular venous plexus, and after standing for 25min, the mice are centrifuged at 4000rpm for 10min to obtain serum. The levels of triglyceride and cholesterol in the mouse serum were determined according to the kit instructions. The results are shown in tables 1-2.
TABLE 1 fasting plasma glucose assay results for each group of mice (mean. + -. SD, n ═ 10)
Table 2 triglyceride and cholesterol levels (mean ± SD, n ═ 10) in each group of mice
According to experimental results, compared with a negative control group, the blood sugar reducing capsule obtained by the invention can obviously reduce the blood sugar level, triglyceride level and cholesterol level of a mouse. The effect of the preparation method is basically equivalent to that of the positive control group, and even the preparation method described in the example 1 is better than that of the positive control group.
example 1 in comparison with examples 2 to 4, in the case of using the same raw materials, example 1 directly granulated the ginseng extract and the schisandra extract obtained by the alcohol extraction method with the hirsutella hepiali mycelia powder without treatment to obtain capsules, which have a superior hypoglycemic effect than the capsules obtained by other preparation methods (examples 2 to 4); the capsules obtained by the alcohol extraction method (examples 1 and 4) have better blood sugar reduction effect than the capsules obtained by the water extraction method (examples 2 and 3); the capsule prepared by directly mixing the hirsutella hepiali mycelia powder with the ginseng alcohol extract and the schisandra fruit alcohol extract without treatment (example 1) has better blood sugar reducing effect than the capsule prepared by mixing the hirsutella hepiali mycelia powder with the ginseng alcohol extract and the schisandra fruit alcohol extract after alcohol extraction (example 4). Therefore, the preparation method has great influence on the final activity of the medicine.
Compared with the comparative examples 1 to 4, the blood sugar reducing capsules containing the ginseng alcohol extract, the schisandra alcohol extract and the hirsutella hepiali mycelium powder have the advantages that the effect is obviously better than that of the blood sugar reducing capsules prepared by omitting any one of the raw materials, and the synergistic blood sugar reducing effect is achieved by the mutual cooperation of a plurality of traditional Chinese medicine components. Especially, compared with the comparative example 3, the capsule for reducing blood sugar is prepared by only using the ginseng alcohol extract and the schisandra alcohol extract in the comparative example 3, and the hirsutella hepiali mycelium powder is not used, so that the blood sugar reducing effect is very poor, and the hirsutella hepiali mycelium powder plays a vital role in reducing blood sugar.
Claims (6)
1. A capsule for reducing blood sugar containing hirsutella hepiali Chen et Shen mycelium powder is characterized in that the capsule comprises the following raw materials: 200-300 g of hirsutella hepiali Chen et Shen mycelium powder, 270-410 g of fructus Schisandrae chinensis and 240-360 g of ginseng; the preparation method comprises the following steps:
(1) weighing ginseng and schisandra chinensis according to a ratio, cleaning, adding 5-6L of 75 mass percent ethanol, extracting under reflux for 2 times, 1-2 hours each time, filtering the extracting solution, removing the residues, combining the filtrates, performing reduced pressure evaporation, recovering the ethanol, concentrating the filtrate to an extract with the relative density of 1.30-1.35 g/cm 3, drying under reduced pressure to obtain a dry extract, crushing, and sieving with a 80-mesh sieve to obtain a dry extract powder;
(2) Weighing hirsutella hepiali mycelia powder according to a ratio, cleaning, mixing with the dry extract powder obtained in the step (1), wetting with 85% ethanol by mass fraction to prepare soft materials, granulating with a 16-mesh sieve, drying at 55-60 ℃, grading with a 14-mesh sieve, and filling into 0# capsule shells to obtain 0.3 g/granule hirsutella hepiali mycelia powder blood sugar reducing capsules.
2. The hepialus hirsutella mycelium powder blood sugar reducing capsule as claimed in claim 1, wherein the raw materials comprise the following components: 250g of hirsutella hepiali Chen et Shen mycelium powder, 340g of Chinese magnoliavine fruit and 300g of ginseng.
3. The hepialus hirsutella mycelium powder hypoglycemic capsule of claim 1, wherein: the reduced pressure evaporation in the step (1) is carried out under the conditions of-0.065 to-0.075 MPa and 65 ℃.
4. The hepialus hirsutella mycelium powder hypoglycemic capsule of claim 3, wherein: the reduced pressure drying condition of the step (1) is-0.085 Mpa and 65 ℃.
5. the hepialus hirsutella mycelium powder hypoglycemic capsule of claim 3, wherein: and (3) the granulation in the step (2) is 16-mesh granulation, and the whole granules are 14-mesh granules.
6. The use of the hirsutella hepiali Chen et Shen mycelia powder hypoglycemic capsules as claimed in claim 1 or 2 in the preparation of hypoglycemic drugs or health products.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710014390.1A CN106619972B (en) | 2017-01-10 | 2017-01-10 | Capsule for reducing blood sugar containing hirsutella hepiali Chen et Shen mycelium powder, and its preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710014390.1A CN106619972B (en) | 2017-01-10 | 2017-01-10 | Capsule for reducing blood sugar containing hirsutella hepiali Chen et Shen mycelium powder, and its preparation method and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106619972A CN106619972A (en) | 2017-05-10 |
| CN106619972B true CN106619972B (en) | 2019-12-10 |
Family
ID=58844327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710014390.1A Active CN106619972B (en) | 2017-01-10 | 2017-01-10 | Capsule for reducing blood sugar containing hirsutella hepiali Chen et Shen mycelium powder, and its preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106619972B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112617187A (en) * | 2020-12-30 | 2021-04-09 | 广东粤微食用菌技术有限公司 | A capsule prepared from cell wall-broken hirsutella hepiali Chen et Shen mycelia with immunity enhancing effect, and its preparation method and application |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101720964A (en) * | 2009-12-02 | 2010-06-09 | 长白朝鲜族自治县松云野生经济植物有限责任公司 | Health-care drink prepared from shizandra berries |
| CN105998117A (en) * | 2016-07-01 | 2016-10-12 | 中国人民解放军海军医学研究所 | Compound capsule with caterpillar fungus, ginseng and oligochitosan and preparation method thereof |
-
2017
- 2017-01-10 CN CN201710014390.1A patent/CN106619972B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101720964A (en) * | 2009-12-02 | 2010-06-09 | 长白朝鲜族自治县松云野生经济植物有限责任公司 | Health-care drink prepared from shizandra berries |
| CN105998117A (en) * | 2016-07-01 | 2016-10-12 | 中国人民解放军海军医学研究所 | Compound capsule with caterpillar fungus, ginseng and oligochitosan and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106619972A (en) | 2017-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107412721B (en) | Blood sugar-reducing bitter gourd polypeptide compound capsule and preparation method thereof | |
| WO2021078288A1 (en) | Activated insulin, compound momordica charantia peptide oral medicine for treatment of diabetes, and preparation method | |
| CN104721301B (en) | A kind of apple polyphenol ethanol extract and its preparation method and application | |
| CN105341893A (en) | Composition for assisting in reducing blood glucose and application | |
| CN106619972B (en) | Capsule for reducing blood sugar containing hirsutella hepiali Chen et Shen mycelium powder, and its preparation method and application | |
| CN111450136B (en) | Oyster and kudzu root composite particles and preparation method thereof | |
| CN105816505A (en) | Chinese herbal medicine compound preparation for treating diabetes and preparation and application of Chinese herbal medicine compound preparation | |
| CN107912771A (en) | A kind of stem of noble dendrobium composition with enhancing immune function and preparation method thereof | |
| CN1262273C (en) | Chinese rose extract and its preparing method and use | |
| CN101167781A (en) | Orally-administered hypoglycemic sweet potato leaf single prescription traditional Chinese medicine and preparation method thereof | |
| CN1209155C (en) | Balsam pear products containing multiple hypoglycemic active composition and preparation thereof | |
| CN102579530A (en) | Preparation method of aralia taibaiensis total saponin having diabetes mellitus resisting effect and medicament | |
| KR100697184B1 (en) | A functional food for a ginseng and mulberry and banaba and the producing method therof | |
| CN109717426A (en) | A kind of hypoglycemia healthcare food and preparation method thereof | |
| CN100400081C (en) | Medicine for treating diabetes and production method thereof | |
| CN1268323C (en) | Rhodiola sacra soft capsule and its preparation | |
| CN105532350B (en) | A kind of preparation method of hainan holly leaf ginkgo biloba extract compound tea | |
| CN107812115A (en) | A kind of Chinese medicine composition for treating diabetes | |
| CN104027363B (en) | A method of extracting an alpha-glucosidase inhibitor from phellinus pini | |
| CN108553559B (en) | Formula and preparation method of vegetable and fruit extract for preventing and treating type II diabetes | |
| CN113663043A (en) | Composition with alpha-glucosidase inhibition effect and preparation method and application thereof | |
| CN106387795A (en) | Rhizoma polygonati odorati, mulberry leaf and royal jelly buccal tablets and production method | |
| CN105535032A (en) | Extraction method of truffle polysaccharides and health-care truffle product | |
| CN105410281A (en) | Preparation method of composite tea composed of extracts of cyclocarya paliurus and gingko | |
| CN108743840A (en) | A kind of Chinese medicine composition and preparation method thereof with auxiliary lipid-lowering function |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |